AGEN NASDAQ
Agenus Inc.
1W: +3.6%
1M: -29.5%
3M: +0.3%
YTD: +105.9%
1Y: +60.6%
3Y: -62.8%
5Y: -93.4%
$6.65
+0.49 (+7.95%)
Weekly Expected Move ±14.6%
$4
$5
$6
$7
$8
Credit Risk of going bust: higher than 86% of companies Debt: 11.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.26 (down 96%), Agenus Inc. would be worth roughly what it owes.
Total debt $40.7M against a stock market value of $300.3M.
Distance to default 2.02 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.1M (short-term plus half of long-term), stock volatility 106.2%; Altman Z'' -40.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.26 (down 96%), Agenus Inc. would be worth roughly what it owes.
Total debt $40.7M against a stock market value of $300.3M.
Distance to default 2.02 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.1M (short-term plus half of long-term), stock volatility 106.2%; Altman Z'' -40.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
26 relationships24
As Filer
counterparties named
2
As Counterparty
mentioned by others
3
Rel. Types
2021-05-18
Earliest Filing
2026-01-16
Latest Filing
partner: 18
investor: 3
acquirer: 3
Counterparties (Filed by AGEN)
24 relationshipsCompanies named in AGEN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | — | partner | Strategic collaborator and acquirer of manufacturing assets | 2026-01-16 | View |
| Zydus Pharmaceuticals (USA) Inc. | — | partner | Wholly-owned subsidiary of Zydus Lifesciences Limited that assigned the purchase agreement | 2026-01-16 | View |
| Zylidac Bio LLC | — | partner | Newly formed subsidiary of Zydus Lifesciences Limited to house acquired manufacturing facilities | 2026-01-16 | View |
| Zynext Ventures USA LLC | ZYXIQ | investor | Wholly-owned subsidiary of ZyNext Ventures PTE. LTD Singapore that purchased Agenus common stock | 2026-01-16 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Entered into an amendment and release agreement regarding liens and warrant exercise price modification. | 2026-01-08 | View |
| MiNK Therapeutics, Inc. | INKT | partner | Shares pledged as collateral for the Promissory Note | 2025-10-09 | View |
| Zydus Pharmaceuticals (USA) Inc. | — | acquirer | Acquired manufacturing assets and entered into a strategic collaboration for BOT/BAL development. | 2025-06-04 | View |
| Zydus Lifesciences Limited | — | partner | Parent of Zydus Pharmaceuticals; entered into exclusive license and manufacturing agreements. | 2025-06-04 | View |
| Zynext Ventures USA LLC | ZYXIQ | investor | Wholly-owned subsidiary of ZyNext Ventures PTE.LTD Singapore; purchased common stock. | 2025-06-04 | View |
| ZyNext Ventures PTE.LTD Singapore | ZYXIQ | investor | Parent of Zynext Ventures USA LLC; made equity investment in Agenus. | 2025-06-04 | View |
| Bristol Myers Squibb Company | CELG-RI | partner | Counterparty to a License, Development and Commercialization Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| Gilead Sciences, Inc. | GILD | partner | Counterparty to an Option and License Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| UroGen Pharma Ltd. | URGN | partner | Counterparty to a License Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| Merck Sharp & Dohme Corp | MRK | partner | Counterparty to a License and Research Collaboration Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| Incyte Europe Sarl | INCY | partner | Counterparty to a License, Development and Commercialization Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| Incyte Corporation | INCY | partner | Counterparty to a License, Development and Commercialization Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | acquirer | Acquired 31.875% of milestone payments, 18.75% of royalties, and a synthetic royalty on net sales of botensilimab and ba | 2024-05-30 | View |
| Incyte Corporation | INCY | partner | Original licensor under a License, Development and Commercialization Agreement with Agenus Inc., whose milestone payment | 2024-05-07 | View |
| Bristol Myers Squibb Company | CELG-RI | partner | Original licensor under a License, Development and Commercialization Agreement with Agenus Inc., whose milestone payment | 2024-05-07 | View |
| Gilead Sciences, Inc. | GILD | partner | Original licensor under an Option and License Agreement with Agenus Inc., whose milestone payments were sold to Ligand. | 2024-05-07 | View |
| UroGen Pharma Ltd. | URGN | partner | Original licensor under a License Agreement with Agenus Inc., whose milestone payments were sold to Ligand. | 2024-05-07 | View |
| Merck Sharp & Dohme Corp | MRK | partner | Original licensor under a License and Research Collaboration Agreement with Agenus Inc., whose milestone payments were s | 2024-05-07 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | acquirer | Acquired 31.875% of milestone payments, 18.75% of royalties, and a synthetic royalty on net sales of botensilimab and ba | 2024-05-07 | View |
| Bristol-Myers Squibb Company | — | partner | Entered into a License, Development and Commercialization Agreement for the anti-TIGIT bispecific antibody program AGEN1 | 2021-05-18 | View |
Mentioned As Counterparty
2 mentionsOther companies that named AGEN in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| LGNZZ LIGAND PHARMACEUTICALS INC | partner | Sellers entering royalty rights agreement with Ligand | 2024-05-07 | View |
| INKT MiNK Therapeutics, Inc. | partner | Entered into an Amended and Restated Intercompany Services Agreement for shared administrative, R&D, and facility suppor | 2022-08-05 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-18 | Material Agreement; Financial Obligation; Unregistered Equity Sales | Agreement | View |
| 2026-08-13 | Officer/Director Change | View | |
| 2026-08-11 | Officer/Director Change | View | |
| 2026-08-06 | Earnings Release | View | |
| 2026-07-13 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-07-06 | Material Agreement | Agreement | View |
| 2026-06-23 | Shareholder Vote | View | |
| 2026-05-15 | Officer/Director Change | View | |
| 2026-05-11 | Earnings Release; Exhibits | View | |
| 2026-03-26 | Other Events | View | |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-16 | Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities; Regulat | Acquisition | View |
| 2026-01-14 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-08 | Entry into Material Definitive Agreement; Material Modification to Rights of Security Holders | Agreement | View |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-09 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2025-09-23 | Other Events | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-20 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-04 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR